A phase I trial of a human papillomavirus DNA vaccine for HPV16+Cervical intraepithelial neoplasia 2/3

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 361-367

  Trimble, Cornelia L ^a,c   Peng, Shiwen ^a   Kos, Ferdynand ^a   Gravitt, Patti ^b   Viscidi, Raphael ^b   Sugar, Elizabeth ^b   Pardoll, Drew ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; PROTEIN E7 HEAT SHOCK PROTEIN 70 FUSION PROTEIN; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLPOSCOPY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; INJECTION SITE DISCOMFORT; MALAISE; MAXIMUM TOLERATED DOSE; MYALGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU; UTERUS BIOPSY; VACCINATION; VAGINA DISCHARGE; VAGINAL DISCOMFORT;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES; VACCINES, DNA;

EID: 58849087222     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1725     Document Type: Article

References (25)

1. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005;11:4717-23.
2. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001;8:209-20.
3. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000:60: 1035-42.
4. Gravitt PE. Reproducibility of HPV16 and HPV18 viral load quantitation using Taq Man real-time PCR assays. J Virol Methods 2003;112:23-33.
5. Sehr P, Zumbach K, Pawlita M A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 2001;253:153-62.
6. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis 2003;3:469-75.
7. Holowaty P, Miller AB, Rohan T.ToT. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-8.
8. Nohr B, Tabor A, Frederiksen K, Kjaer SK. Loopelec trosurgical excision of the cervix and the subsequent risk of preterm delivery. Acta Obstet Gynecol Scand 2007;86:596-603
9. Samson SL, Bentley JR. Fahey TJ, McKay DJ, Gill GH. The effect of loop electrosurgical excision procedure on future pregnancy outcome. Obstet Gynecol 2005; 105:325-32
10. Sjoborg KD, Vistad I, Myhr SS, et al. Pregnancy outcome after cervical cone excision: a case-control study. Acta Obstet Gynecol Scand 2007:86:423-8.
11. Wloch MK, Smith LR, Boutsaboualoy S, et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008;197:1634-42.
12. Keating SM, Bejon P. Berthoud T. et al Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 2005; 175. 5675-80.
13. McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003:9:729-35.
14. Vuola JM, Keating S, Webster DP. et al Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005;174:449 - 55.
15. Goonetilleke N, Moore S, Dally L, et al Induction of multifunctional human immunodeficiency virus type 1 (HlV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8 + T-cell epitopes. J Virol 2006:80:4717 -28.
16. Mwau M. Cebere I, Sutton J, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004:85: 911 -9.
17. Harari A, Bart PA, Stohr W, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008,205:63-77.
18. Chen C. Wang T, Hung C. Pardoll DM. Wu T. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines [In Process Citation]. Vaccine 2000;18:2015-22.
19. Welters MJ, de Jong A, van den Eeden SJ, et al. Frequent display of human papillomavirus type 16 E6-specific memory t-helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003;63:636-41.
20. Gallagher KM, Man S. Identification of HLA- DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women. J Gen Virol 2007;88:1470-8.
21. de Jong A, van Poelgeest Ml, van der Hulst JM, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64:5449-55.
22. Kenter GG, Welters MJ.Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillo-mavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008;14:169-77.
23. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008;8:74-80.
24. Matsumoto K, Leggatt GR, Zhong J, et al. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. J Natl Cancer Inst 2004;96:1611 -9.
25. van Poelgeest Ml, van Seters M, van Beurden M, et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005;11:5273-80.